

Haematologica
HAEMATOL/2020/260430
Version 4

Efficacy of UVC-treated, pathogen-reduced platelets versus untreated platelets: a randomized controlled non-inferiority trial

Veronika Brixner, Gesine Bug, Petra Pohler, Doris Krämer, Bernd Metzner, Andreas Voß, Jochen Casper, Ulrich Ritter, Stefan Klein, Nael Alakel, Rudolf Peceny, Hans G. Derigs, Frank Stegelmann, Martin Wolf, Hubert Schrezenmeier, Thomas Thiele, Erhard Seifried, Hans-Hermann Kapels, Andrea Döscher, Eduard K. Petershofen, Thomas H. Müller, and Axel Seltsam

Disclosures: V.B. received grants from the Research Foundation of the German Red Cross Blood Services (Forschungsgemeinschaft der Blutspendedienste des Deutschen Roten Kreuzes) and Macopharma for the development of the UVC-based PI technology for platelets and from CERUS for a clinical trial on PI technology for Red Blood Cells. G.B. received departmental research funding from Novartis, travel grants from Celgene, Gilead, Neovii and Sanofi and honoraria for advisory board memberships for Celgene, Eurocept, Gilead, Hexal, Novartis, Pfizer and Jazz. P.P. received grants from the Research Foundation of the German Red Cross Blood Services (Forschungsgemeinschaft der Blutspendedienste des Deutschen Roten Kreuzes) and Macopharma for the development of the UVC-based PI technology for platelets. J.C. received consultancy fee from Pfizer, Merck, Ipsen, Medac; speaker's bureau fees from Pfizer, Merck, Ipsen, Medac; served as consultant for Pfizer, Merck, Ipsen, Medac; received research funding from Ipsen, Medac; reports membership of the Federal Joint Committee (G-BA) Public Policy and Strategy Committee (non-profit). U.R. received department honoraria for advisory board memberships for Pfizer, Daiichi-Sankyo, Jazz, Servier and Novartis. N.A. received speaker's bureau fees from Basilea Pharmaceutica, honoraria for advice from Gilead, MSD Sharp & Dohme GmbH, Pfizer, Amgen and travel grants from Gilead, MSD Sharp & Dohme GmbH, Pfizer, Amgen. R.P. received consulting fee from Sanofi Genzyme and Pfizer, and received travel and accommodation expenses from Bristol-Myers Squibb. T.T. received personal fees from Bristol Myers Squibb, Bayer, Daichii Sankyo, Pfizer, Novo Nordisk, Chugai Pharma and Novartis. T.H.M. received grants from the Research Foundation of the German Red Cross Blood Services (Forschungsgemeinschaft der Blutspendedienste des Deutschen Roten Kreuzes) and Macopharma for the development of the UVC-based PI technology for platelets, and reports membership for advisory boards (non-profit) for three German Blood Services (Jena, Rostock, Suhl). A.S. received grants from the Research Foundation of the German Red Cross Blood Services (Forschungsgemeinschaft der Blutspendedienste des Deutschen Roten Kreuzes) and Macopharma for the development of the UVC-based PI technology for platelets, and honoraria for advisory board memberships for Grifols, Quotient and Imusyn. D.K., B.M., A.V., S.K., H.G.D., F.S., M.W., H.S., E.S., H.-H. K., A.D. and E.K.P. have no conflicts of interest to disclose.

Contributions: A.S., G.B., T.H.M., P.P., V.B. contributed to the conception and design of the study. G.B., V.B., D.K., B.M., A.V., J.C., U.R., S.K., N.A., R.P., H.G.D., F.S., M.W., H.S., T.T., H.-H. K., A.D., E.K.P. contributed to the acquisition of data. A.S., T.H.M., P.P. analyzed and interpreted the data and wrote the manuscript. G.B and E.S contributed to the interpretation of the data. All authors critically reviewed and revised the manuscript content and checked the final version of the manuscript. All authors are accountable for all aspects of the work.